dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Fivefold difference found in Medicaid reimbursements for radiotherapy May limit access to healthcare, especially in rural areas

Trends in radiation oncology workforce potentially threaten rural patients, says study More radiation oncologists leaving, fewer coming in to rural areas

Varian showcases first preclinical findings of Flash therapy trial Reductions in radiation lung fibrosis and dermatitis

Female oncologists submit fewer charges, paid less than male Study bases findings on Medicare records

Four considerations before embarking on a carbon therapy center The next frontier in improving cancer care

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

Q&A with Scott Warwick, executive director of the National Association for Proton Therapy Find out what to expect at the year's biggest proton therapy industry event

Aussies and Americans develop 3D models for assessing impacts of radiotherapy Test different levels and types of radiation

Law in Ontario prevents cremation of brachytherapy patients Experts call for eliminating the law, as it deters patients from lifesaving treatment

IBA tech plays first-time role in flash therapy demonstration Supports eventual integration of flash as clinical treatment

Dimitris Bertsimas

Big data targets best cancer treatments

by John W. Mitchell , Senior Correspondent
When his father was diagnosed with Stage 4 gastric cancer in 2007, Dimitris Bertsimas, co-director of the Operations Research Center at MIT, Sloan School of Management, did what any son would do. He took his father to the best cancer centers in the region for three opinions. That’s were the confusion began.

“I got three different opinions about what chemo treatments my father should receive,” Bertsimas told HCB News. “It was very confusing and I couldn’t figure out what to do.”

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



The three different treatment protocols each had different tradeoffs between survivability and toxicity. Bertsimas ended up applying his expertise in applied mathematics to do a few quick calculations on the back of an envelope to help him decide what was the best chemo treatment for his father. His father, who only had a life expectancy of eight months, lived “reasonably well” for two more years.

This experience led to a large-scale study just published in Management Science. The research unleashed the power of big data to create an efficacy model to predict the best outcomes for Stage 2 and Stage 3 gastric and gastro-esophageal cancers. The study compiled a database of over 400 published clinical papers.

According to Bertsimas, the big data approach was able to identify the optimal chemo treatment options for gastric cancer patients to extend survivability for, on average, four months.

“Our main objective was [to] find a way to help patients and doctors to make individualized decisions about the most effective treatments,” he said. “The way treatment decisions are made now is very much based on intuition and on the luck of the draw.”

He said patients usually go to one doctor whose recommendation tends to be based on their own experience. That’s because a physician may only know about one or two treatment chemo protocols that may not be an ideal option for that patient compared to other proven treatments.

Bertsimas said that big data solutions could also assist pharmaceutical companies in clinical trials. The government could also benefit in its quest to find the best outcomes for the most affordable costs.

Bertsimas and his team are now working to compile and analyze breast and prostate cancer big databases. The gastric big database results and recommendations are being rolled out for clinical trials with patients at three hospitals, including Presbyterian New York and The Dana Farber Cancer Center. The goal will be to offer the same two-dimensional comparison of toxicity and survivability Bertsimas relied on to help his father.

“I feel the era of big data in medicine to develop predictive and prescriptive analysis is very promising,” he said. “It utilizes the totality of the data the entire medical community — really all of human knowledge — has created.”

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED